Skip to main content

News

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis

Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoi

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

Repeat Malignancy Unlikely with Biologic Therapy

Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

Opportunistic Infections in RA Rare with Biologics

The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics. 

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

Bone Marrow Edema Found in SI Joint of Athletes

New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.

Plaquenil During Lupus Pregnancy Lessens Flares

A large cohort study of pregnant and non-pregnant women with systemic lupus erythematosus has shown that lupus flares are increased during pregnancy and in the 3  months follwing delivery.

Limited Utility of Arthroscopic Meniscal Surgery

JAMA Surgery reports that arthroscopic partial meniscectomy (APM) is still one of the most common surgeries performed, despite evidence from large trials (eg, FIDELITY study) showing that APM is no more effective than exercise and physical therapy, especially in adults over age 65 years.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

Biologics in Pregnancy: Are They Safe?

Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.

DSB – Safety Updates & Drug Shortages – March 2018

This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages. 

×